Abstract:Natural products (NPs) continue to provide a structural template for the design of novel therapeutic agents and expedite the drug discovery process. The majority of FDA-approved pharmaceuticals used in medical practice can be traced back to natural sources, and NPs play a significant role in drug development. Curcumin, one of the most well-studied chemicals among the NPs, is currently the subject of intense investigation for its biological effects, including the prevention and treatment of cancer. Cancer has overtaken all other causes of death in the world today, with 19.3 million new cases and nearly 10 million deaths predicted in 2020. In the present investigation, we reported the synthesis of three semi-synthetic analogues of curcumin-bearing pyrimidinone moiety by the chemical modification of the diketone function of curcumin followed by their characterization by analytical techniques including infrared (IR), nuclear magnetic resonance (NMR), and mass spectral data. According to the National Cancer Institute (NCI US) methodology, the curcumin analogues (C1-C3) were tested for their anticancer efficacy against 59 cancer cell lines in a single dose assay. 1-(2,6-Dichlorophenyl)-4,6-bis((E)-4-hydroxy-3-methoxystyryl)pyrimidin-2(1H)-one (C2) demonstrated the most promising anticancer activity with mean percent growth inhibition (%GIs) of 68.22 in single dose assay at 10 µM. The compound exhibited >68 %GIs against 31 out of 59 cancer cell lines and was found to be highly active against all leukemia and breast cancer cell lines. The compound C2 showed a lethal effect on HT29 (colon cancer) with %GI of 130.44, while 99.44 %GI was observed against RPMI-8226 (Leukemia). The compound C2 displayed better anticancer activity against the panels of CNS, melanoma, ovarian, prostate, and breast cancer cell lines than curcumin and other anti-EGFR agents gefitinib and imatinib in single dose assay. The compound C2 also demonstrated potent anticancer activity in a 5-dose assay (0.001 to 100 µM) with GI50 values ranging from 1.31 to 4.68 µM; however, it was found to be non-selective with SR values ranging from 0.73 to 1.35. The GI50 values of compound C2 were found to be better than that of the curcumin against all nine panels of cancer cell lines. All of the curcumin analogues were subsequently investigated for molecular docking simulation against EGFR, one of the most attractive targets for antiproliferative action. In molecular docking studies, all the ligands were found to accommodate the active site of EGFR and the binding affinity of ligand C2 was found to be −5.086 kcal/mol. The ligand C2 exhibited three different types of interactions: H-bond (Thr790 and Thr854), π-cationic (Arg841), and aromatic H-bond (Asn842). The curcumin analogues reported in the current investigation may provide valuable therapeutic intervention for the prevention and treatment of cancer and accelerate anticancer drug discovery programs in the future.

Curcumin-Conjugated PAMAM Dendrimers of Two Generations: Comparative Analysis of Physiochemical Properties Using Adriatic Topological Indices

Innovative Delivery Systems for Curcumin: Exploring Nanosized and Conventional Formulations

Synthesis, structure determination, molecular interaction, optical, thermal and anticancer activity studies, pharmacokinetic evaluation, and in-silico analysis of monocarbonyl curcumin derivative: An approach to drug discovery

Potential of Poly(amidoamine) Dendrimers As Drug Carriers of Camptothecin Based on Encapsulation Studies.

Pegylated Curcumin Derivative: Water-Soluble Conjugates with Antitumor and Antibacterial Activity

Physicochemical investigation of a novel curcumin diethyl γ-aminobutyrate, a carbamate ester prodrug of curcumin with enhanced anti-neuroinflammatory activity

Synthesis, characterization, quantum mechanical calculations and biomedical docking studies on curcumin analogs: 2, 6-(Difurfurylidene) cyclohexanone and 2, 6 - Bis (2,6-Dichloro Benzylidene) Cyclohexanone

Design, synthesis, biological evaluation and in silico studies of curcumin pyrrole conjugates

DESIGN, PREPARATION, AND IN SILICO STUDY OF NOVEL CURCUMIN-BIPHENYL CARBONITRILE CONJUGATE AS NOVEL ANTICANCER DRUG MOLECULES

Pharmacological safety of dimethoxy curcumin-human serum albumin conjugate for potential therapeutic purpose

Mono-Dendronized β-Cyclodextrin Derivatives as Multitasking Containers for Curcumin. Impacting Its Solubility, Loading, and Tautomeric Form

Preparation of curcumin-loaded MPEG-PTMC nanoparticles: Physicochemical properties, antioxidant activity, and in vivo pharmacokinetic behavior

The Chemistry of Curcumin: From Extraction to Therapeutic Agent

Molecular Interactions for the Curcumin-Polymer Complex with Enhanced Anti-Inflammatory Effects

Synthesis, characterization and fluorescent properties of water-soluble glycopolymer bearing curcumin pendant residues

Chemical Modification of Curcumin into Its Semi-Synthetic Analogs Bearing Pyrimidinone Moiety as Anticancer Agents

Preformulation Studies and Bioavailability Enhancement of Curcumin with a 'Two in One' PEG-β-Cyclodextrin Polymer

Study of a Water-Soluble Supramolecular Complex of Curcumin and Β-Cyclodextrin Polymer with Electrochemical Property and Potential Anti-Cancer Activity

Unravel the Tangle: Atomistic Insight into Ultrahigh Curcumin-Loaded Polymer Micelles

Elaboration and Characterization of Curcumin-Loaded Tri-CL-mPEG Three-Arm Copolymeric Nanoparticles by a Microchannel Technology

Curcumin-tannic acid-poloxamer nanoassemblies enhance curcumin's uptake and bioactivity against cancer cells in vitro